I think you know the answer to that Orlando. If we are not uplisted by then, we don't get the shares. However, does it really matter? When we get the shares, our share price will automatically get cut in half (actually slightly less due to the extra 9M shares). That doesn't mean the share price will stay there. Being on the Nasdaq will bring in new investors, institutions, etc which may drive the share price back up.
However if we don't get the shares, and the price is higher like it is, you still have the same Market value in your portfolio. It is just that we will still be on the bully boards and most likely the price will drop, unless revenues are starting to come in nicely.
I think bringing on Donahue, and their list of clients, ensures we have the best chance of uplisting.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.